Experimental antibody relieves pruritus in atopic dermatitis
The results come from a four-month phase 3 clinical trial
Subcutaneous abdominal injections of the experimental monoclonal antibody nemolizumab produced significant improvement in patients with atopic dermatitis and moderate-to-severe pruritus, a study shows.
The improvements were seen in several measures of disease severity during the 16-week, phase 3 double-blinded trial carried out in 215 Japanese volunteers, all aged 13 or older.
The antibody, given every four weeks, works against the interleukin-31 receptor A, known to be involved with pruritus and inflammation in atopic